Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ENSC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsEnsysce Biosciences reports Q1 2026 financial results
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release disclosing financial results for the quarter ended March 31, 2026. Specific figures and performance metrics are contained in the attached exhibit.
Item 2.02 verify on EDGAR → -
low
This is a routine quarterly earnings disclosure filed via Form 8-K. The filing itself contains no financial details beyond referencing the press release attachment.
8-K: Earnings view on EDGAR →
Summary
Ensysce Biosciences filed an 8-K to announce its first quarter 2026 financial results through a press release dated May 15, 2026. This is a standard quarterly earnings disclosure required for public companies. The filing itself is procedural, with the actual financial performance details contained in the attached press release exhibit.
For retail investors, the key information—revenue, expenses, cash position, and any operational updates—will be in the press release itself, not this 8-K cover filing. Investors should review the full press release (Exhibit 99.1) to understand the company's Q1 performance and any forward-looking guidance management provided. Watch for any conference call details where management typically discusses results and answers analyst questions about the quarter's performance and outlook.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Ensysce Biosciences announced Q1 2026 financial results via press release; full details in Exhibit 99.1.
Added in current filing · verify on EDGAR →
On May 15, 2026, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.
The company disclosed its financial results for the quarter ended March 31, 2026 through a press release. The actual financial figures and performance metrics are contained in Exhibit 99.1, which is referenced but not included in the 8-K body text provided.
Event · Item 9.01 — Financial Statements and Exhibits
Ensysce Biosciences filed an 8-K attaching a press release dated May 15, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
99.1 Press Release, dated May 15, 2026
The 8-K references an attached press release dated May 15, 2026, but the filing body provides no details about the content or subject matter of that release. Without access to Exhibit 99.1, the materiality and investor impact cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 26, 2026 · How we verify